Trial
NCT01480817
Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Seoul National University Hospital
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
Sorafenib
Why stopped
Difficulty of participant enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-29